JP2005521401A - ポリペプチド産生を増加させる方法 - Google Patents

ポリペプチド産生を増加させる方法 Download PDF

Info

Publication number
JP2005521401A
JP2005521401A JP2003580502A JP2003580502A JP2005521401A JP 2005521401 A JP2005521401 A JP 2005521401A JP 2003580502 A JP2003580502 A JP 2003580502A JP 2003580502 A JP2003580502 A JP 2003580502A JP 2005521401 A JP2005521401 A JP 2005521401A
Authority
JP
Japan
Prior art keywords
polypeptide
cell line
temperature
mmol
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003580502A
Other languages
English (en)
Japanese (ja)
Inventor
バンネス，カーク・ピー
トレンタランジェ，マイケル・ティー
デル，ブラッドレー・ディー
マックグリュー，ジェフリー・ティー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28678222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005521401(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of JP2005521401A publication Critical patent/JP2005521401A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2003580502A 2002-03-27 2003-03-27 ポリペプチド産生を増加させる方法 Pending JP2005521401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36824802P 2002-03-27 2002-03-27
US36824602P 2002-03-27 2002-03-27
PCT/US2003/009266 WO2003083066A2 (en) 2002-03-27 2003-03-27 Methods for increasing polypeptide production

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2008024395A Division JP4414466B2 (ja) 2002-03-27 2008-02-04 ポリペプチド産生を増加させる方法
JP2008301520A Division JP4414472B2 (ja) 2002-03-27 2008-11-26 ポリペプチド産生を増加させる方法

Publications (1)

Publication Number Publication Date
JP2005521401A true JP2005521401A (ja) 2005-07-21

Family

ID=28678222

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003580502A Pending JP2005521401A (ja) 2002-03-27 2003-03-27 ポリペプチド産生を増加させる方法
JP2008024395A Expired - Lifetime JP4414466B2 (ja) 2002-03-27 2008-02-04 ポリペプチド産生を増加させる方法
JP2008301520A Expired - Lifetime JP4414472B2 (ja) 2002-03-27 2008-11-26 ポリペプチド産生を増加させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008024395A Expired - Lifetime JP4414466B2 (ja) 2002-03-27 2008-02-04 ポリペプチド産生を増加させる方法
JP2008301520A Expired - Lifetime JP4414472B2 (ja) 2002-03-27 2008-11-26 ポリペプチド産生を増加させる方法

Country Status (9)

Country Link
US (2) US6872549B2 (cg-RX-API-DMAC7.html)
EP (1) EP1497444B1 (cg-RX-API-DMAC7.html)
JP (3) JP2005521401A (cg-RX-API-DMAC7.html)
AU (1) AU2003220529B2 (cg-RX-API-DMAC7.html)
CA (1) CA2480121C (cg-RX-API-DMAC7.html)
ES (1) ES2557741T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009381A (cg-RX-API-DMAC7.html)
PL (1) PL376821A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003083066A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049567A1 (ja) * 2005-10-24 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 物質の製造方法
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
JP2021500069A (ja) * 2017-10-23 2021-01-07 プロゲン・シーオー., エルティーディー.Progen Co., Ltd. 改変ｅｇｆタンパク質、その製造方法及びその使用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
EP1497444B1 (en) * 2002-03-27 2015-11-04 Immunex Corporation Methods for increasing polypeptide production
WO2004046340A2 (en) * 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
MXPA05011486A (es) * 2003-04-25 2006-04-18 Immunex Corp Inductores de expresion de proteina recombinante.
US20050112194A1 (en) * 2003-08-21 2005-05-26 Duchesnay Inc. Micronutrient supplement dispensing package
US20050112211A1 (en) * 2003-08-21 2005-05-26 Eric Gervais Micronutrient supplement
US20070099266A1 (en) * 2003-12-23 2007-05-03 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
SI1969007T1 (sl) 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
DK1987068T3 (en) 2006-02-10 2018-09-03 Life Technologies Corp OLIGOSACCHARID MODIFICATION AND LABELING OF PROTEINS
AU2007339423B2 (en) * 2006-08-14 2012-11-15 Biocontrol Systems, Inc. Method for detecting pathogens
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
KR20090074040A (ko) 2006-09-13 2009-07-03 아보트 러보러터리즈 세포 배양의 개선
TW200907062A (en) * 2007-03-28 2009-02-16 Medarex Inc Methods of gene amplification and expression
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
BR112012013330A2 (pt) * 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
WO2012043754A1 (ja) 2010-09-30 2012-04-05 ダイキン工業株式会社 ドリップ防止剤、並びに、樹脂組成物
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
LT2726600T (lt) 2011-07-01 2017-05-25 Amgen Inc. Žinduolių ląstelių kultūra
EP2653548A1 (de) 2012-04-17 2013-10-23 Greenovation Biotech GmbH Verfahren zur Erhöhung der Sekretion rekombinanter Proteine
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EA201591481A1 (ru) * 2013-03-15 2016-02-29 Теокорп Холдинг Компани, Ллс Теоброминовые композиции, применимые для увеличения привеса плода и улучшения свойств кости
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA3040899A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR102190790B1 (ko) * 2018-10-19 2020-12-15 주식회사 프로젠 변형된 egf 단백질의 생산 방법
KR20230124578A (ko) 2020-12-22 2023-08-25 암젠 인크 세포 배양 방법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3824286A (en) 1970-07-07 1974-07-16 Lever Brothers Ltd Preparation of polyacetylalkylene diamines
DE2961658D1 (en) 1978-05-17 1982-02-18 Thomae Gmbh Dr K Process for preparing human interferon
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
US4357422A (en) 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4416986A (en) 1981-01-16 1983-11-22 Merck & Co., Inc. Methods of producing HBsAg
US4473647A (en) 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4992472A (en) 1987-06-16 1991-02-12 The United States Of America As Represented By The Department Of Health And Human Services Chemical differentiating agents
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5330744A (en) 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
ZA899421B (en) 1988-12-14 1990-09-26 Merrell Dow Pharma Method of potentiating natural killer cell activity
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US20010010922A1 (en) 1994-06-09 2001-08-02 Riccardo Dalla-Favera Cloning and uses of the genetic locus bcl-6
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1998028010A2 (en) 1996-12-24 1998-07-02 Hyal Pharmaceutical Corporation Use of moieties for binding to hyaluronan and icam-1
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1663599A (en) 1997-12-19 1999-07-12 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
JP2002526109A (ja) 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE60032349T2 (de) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
NZ518388A (en) 1999-10-13 2003-10-31 Immunex Corp Vectors for recombinant protein expression containing polyadenylation sites from SV40 virus and internal ribosome entry sites (IRES).
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
WO2001083525A2 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
EP1497444B1 (en) * 2002-03-27 2015-11-04 Immunex Corporation Methods for increasing polypeptide production

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049567A1 (ja) * 2005-10-24 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 物質の製造方法
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
JP2021500069A (ja) * 2017-10-23 2021-01-07 プロゲン・シーオー., エルティーディー.Progen Co., Ltd. 改変ｅｇｆタンパク質、その製造方法及びその使用

Also Published As

Publication number Publication date
EP1497444A2 (en) 2005-01-19
PL376821A1 (pl) 2006-01-09
US20050233415A1 (en) 2005-10-20
WO2003083066A2 (en) 2003-10-09
JP2009082138A (ja) 2009-04-23
JP4414472B2 (ja) 2010-02-10
AU2003220529B2 (en) 2006-09-07
EP1497444A4 (en) 2006-08-30
US7452695B2 (en) 2008-11-18
US20030211579A1 (en) 2003-11-13
EP1497444B1 (en) 2015-11-04
AU2003220529A1 (en) 2003-10-13
JP2008167760A (ja) 2008-07-24
ES2557741T3 (es) 2016-01-28
JP4414466B2 (ja) 2010-02-10
WO2003083066A3 (en) 2004-02-26
MXPA04009381A (es) 2005-01-25
CA2480121A1 (en) 2003-10-09
US6872549B2 (en) 2005-03-29
CA2480121C (en) 2012-02-28

Similar Documents

Publication Publication Date Title
JP4414466B2 (ja) ポリペプチド産生を増加させる方法
JP4510938B2 (ja) 哺乳動物細胞により産生されるタンパク質のシアル酸付加を調節する方法および培地
US20200080049A1 (en) Feed media
US6890736B1 (en) Methods for producing proteins in cultured cells
US20040265964A1 (en) Inducers of recombinant protein expression
CA2762016C (en) Methods for increasing polypeptide production

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080728